California’s top court appeared reluctant on Wednesday to open the door to a sweeping new legal obligation that could force pharmaceutical companies to continuously pursue “better” versions of already approved medicines.
At the center of the dispute is biotechnology giant Gilead Sciences, now facing claims from nearly 24,000 HIV patients who argue the company intentionally delayed a newer formulation of its treatment in order to extend profits from an older drug lineup.
The case could reshape the boundaries of product liability law in the pharmaceutical industry. If the plaintiffs succeed, drugmakers may face future lawsuits not because a medicine was unsafe, but because a supposedly safer alternative was not brought to market quickly enough.
During oral arguments, several justices of the California Supreme Court questioned whether courts and juries should be placed in the role of second-guessing scientific development strategies years after the fact.
Justice Goodwin Liu openly wondered whether the issue belonged in the legislature rather than the courtroom, signaling concern about imposing broad legal duties tied to corporate research choices. Other members of the bench echoed worries that punishing companies for development decisions could discourage innovation rather than promote it.
The litigation revolves around HIV medications built on tenofovir disoproxil fumarate, commonly known as TDF. Those treatments received federal approval in 2001 and became widely used, though they carried known risks involving kidney and bone health in some patients.
Gilead later explored another compound — tenofovir alafenamide fumarate, or TAF — which plaintiffs say was gentler on the body. According to the patients, the company shelved TAF development for years despite knowing it could reduce harmful side effects.
Lawyers representing the patients argued that the delay was financially motivated. They accused Gilead of timing the eventual release of TAF-based drugs to align with the approaching expiration of patent protections surrounding TDF medications, allowing the company to maximize billions in revenue.
In court, plaintiffs painted a stark picture, alleging the company knowingly allowed patients to continue using harsher drugs while protecting its market dominance.
Gilead rejected those accusations and insisted its conduct reflected legitimate scientific and business judgment, not negligence. The company’s legal team argued that TDF treatments were approved as safe and effective, and said the plaintiffs were attempting to invent an unprecedented legal theory that would leave pharmaceutical manufacturers exposed whenever a newer product might later appear preferable.
One justice questioned where the line would be drawn if courts began treating alternative research paths as evidence of negligence, especially when the original medication successfully treated life-threatening disease.
Gilead maintained that its earlier HIV therapies transformed treatment by enabling simpler once-daily dosing and saving millions of lives worldwide.
The company’s shares rose modestly during trading as arguments unfolded.
The California Supreme Court did not indicate when it plans to issue its ruling.
